WO1998021231A2 - Streptococcus uberis lactoferrin-binding protein - Google Patents
Streptococcus uberis lactoferrin-binding protein Download PDFInfo
- Publication number
- WO1998021231A2 WO1998021231A2 PCT/CA1997/000867 CA9700867W WO9821231A2 WO 1998021231 A2 WO1998021231 A2 WO 1998021231A2 CA 9700867 W CA9700867 W CA 9700867W WO 9821231 A2 WO9821231 A2 WO 9821231A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- uberis
- binding
- binding protein
- protein
- blf
- Prior art date
Links
- 241000194054 Streptococcus uberis Species 0.000 title claims abstract description 167
- 229940115922 streptococcus uberis Drugs 0.000 title claims abstract description 12
- 102100032241 Lactotransferrin Human genes 0.000 title claims 4
- 108091008324 binding proteins Proteins 0.000 claims abstract description 75
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 74
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 claims abstract description 35
- 208000004396 mastitis Diseases 0.000 claims abstract description 32
- 229960005486 vaccine Drugs 0.000 claims abstract description 32
- 208000015181 infectious disease Diseases 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 45
- 241000283690 Bos taurus Species 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 239000000523 sample Substances 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 108091026890 Coding region Proteins 0.000 claims description 28
- 230000002163 immunogen Effects 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 185
- 230000001105 regulatory effect Effects 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 17
- 229940072440 bovine lactoferrin Drugs 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 137
- 235000018102 proteins Nutrition 0.000 description 131
- 230000027455 binding Effects 0.000 description 109
- 101150072740 Lbp gene Proteins 0.000 description 105
- 210000004027 cell Anatomy 0.000 description 87
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 44
- 241000588724 Escherichia coli Species 0.000 description 42
- 241000894006 Bacteria Species 0.000 description 38
- 235000013336 milk Nutrition 0.000 description 38
- 239000008267 milk Substances 0.000 description 38
- 210000004080 milk Anatomy 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 33
- 230000001580 bacterial effect Effects 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 25
- 108010076504 Protein Sorting Signals Proteins 0.000 description 25
- 229940098773 bovine serum albumin Drugs 0.000 description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 229910052742 iron Inorganic materials 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 22
- 239000012528 membrane Substances 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 210000004379 membrane Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 14
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 14
- 102000010445 Lactoferrin Human genes 0.000 description 14
- 210000002421 cell wall Anatomy 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
- 235000013365 dairy product Nutrition 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000004202 carbamide Substances 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 210000005075 mammary gland Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 210000001082 somatic cell Anatomy 0.000 description 11
- 108010063045 Lactoferrin Proteins 0.000 description 10
- 101710085938 Matrix protein Proteins 0.000 description 10
- 101710127721 Membrane protein Proteins 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 239000000539 dimer Substances 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 235000021242 lactoferrin Nutrition 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108091081024 Start codon Proteins 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 101150101515 tbpl2 gene Proteins 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229940078795 lactoferrin Drugs 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 102000004338 Transferrin Human genes 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000012581 transferrin Substances 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 108090000901 Transferrin Proteins 0.000 description 6
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- -1 heme compounds Chemical class 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000006651 lactation Effects 0.000 description 6
- 108010071397 lactoferrin receptors Proteins 0.000 description 6
- 210000004897 n-terminal region Anatomy 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 239000012130 whole-cell lysate Substances 0.000 description 6
- 101710189078 Helicase Proteins 0.000 description 5
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- 101150048353 Mga gene Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000006161 blood agar Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000007899 nucleic acid hybridization Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 101000766308 Bos taurus Serotransferrin Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 4
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 241000588653 Neisseria Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 239000000589 Siderophore Substances 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 239000000304 virulence factor Substances 0.000 description 4
- 230000007923 virulence factor Effects 0.000 description 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- 208000031462 Bovine Mastitis Diseases 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287227 Fringillidae Species 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 229960000958 deferoxamine Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000050459 human LTF Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 101150102688 lbpA gene Proteins 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 108010010318 streptococcal M protein Proteins 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241001669573 Galeorhinus galeus Species 0.000 description 2
- 101000812705 Gallus gallus Endoplasmin Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 102000028555 IgG binding proteins Human genes 0.000 description 2
- 108091009325 IgG binding proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000010638 Kinesin Human genes 0.000 description 2
- 108010063296 Kinesin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001625930 Luria Species 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- YKUPBWMOBLEEMC-UHFFFAOYSA-N (5-bromo-4-chloro-1H-indol-3-yl) phosphate 2H-tetrazol-1-ium Chemical compound C=1N=NN[NH+]=1.C=1N=NN[NH+]=1.C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 YKUPBWMOBLEEMC-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100508415 Caenorhabditis elegans ifc-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101150101131 FABP7 gene Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 102000028556 IgA binding proteins Human genes 0.000 description 1
- 108091009322 IgA binding proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000034782 Lid sulcus deepened Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241001440871 Neisseria sp. Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000196250 Prototheca Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102100036164 Putative phospholipase B-like 2 Human genes 0.000 description 1
- 101710200837 Putative phospholipase B-like 2 Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101150088541 SCPA gene Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 1
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003095 anti-phagocytic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 244000000015 environmental pathogen Species 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108091009104 fibrinogen binding proteins Proteins 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229940052778 neisseria meningitidis Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 101150040063 orf gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 101150033155 sspP gene Proteins 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates generally to bacterial antigens. More particularly, the present invention pertains to the characterization and recombinant production of a bovine lactoferrin-binding protein from Streptococcus uberis ( S . uberis) and the use of the same. The invention also relates to the characterization of a regulatory region, mga, located upstream of the lactoferrin-binding protein gene.
- Streptococcus uberis S . uberis
- S . uberis is an environmental pathogen responsible for a high proportion of cases of mastitis in lactating cows and is the predominant organism isolated from mammary glands during the nonlactating period (Bramley, A.J. (1984) Br. Vet . J. 140:328-335; Bramley and Dodd (1984) J. Dairy Res . 51:481-512; Oliver, S.P. (1988) Am . J. Vet . Res . 4.9:1789-1793) . Mastitis resulting from infection with S .
- S . uberis mastitis may also take the form of an acute clinical condition, with obvious signs of disease such as clots or discoloration of the milk and swelling or hardness of the mammary gland. Some cases of the clinical disease can be severe and pyrexia may be present.
- S . uberis mastitis see, Bramley (1991) Mastitis: physiology or pathology, p.
- S . uberis infection The pathogenesis of S . uberis infection is poorly understood. Furthermore, the influence of S . uberis virulence factors on host defense mechanisms and mammary gland physiology is not well defined. Known virulence factors associated with S . uberis include a hyaluronic acid capsule, hyaluronidase, R- like protein, plasminogen activator and CAMP factor. However, very little is known of their roles in pathogenicity.
- Lactoferrin is a mammalian iron-binding glycoprotein secreted by polymorphonuclear leukocytes (PM ⁇ s) and various exocrine glands (Baggiolini et al . (1970) J " . Exp . Med . 131: 559-570 ; Masson et al . (1966) Clin . Chim . Acta 14:735-739) . This protein is found at high concentrations in milk and at mucosal surfaces (Masson et al . , supra; Reiter and Oram (1967) Nature 216:328-330) .
- bovine lactoferrin (bLf) concentrations in lacteal secretions can increase up to 30 -fold during acute bovine mastitis, depending on the severity of infection (Harmon et al . (1976) Infect . Immun . 13:533-542) .
- Lf A regulatory function for Lf in various physiological pathways, including the adhesion of PM ⁇ s to the endothelial surface, feedback inhibition of the granulocyte-monocyte colony-stimulating factor, and the regulation of antibody production, has been suggested.
- Specific interaction of Lf with certain mammalian cells seems to be involved in the above pathways and specific receptors for Lf have been identified on macrophages, monocytes, B lymphocytes, PMNs, activated T lymphocytes, and hepatocytes (Bennet and Davis (1981) J " . Immunol . 127:1211-1216; Dehanne et al. (1985) Am . J. Physiol . 248:463-469: Maneva et al . (1983) Int .
- Lf inhibits the growth of E. coli and certain other microorganisms in vi tro (Bullen et al . (1972) Br. Med . J. 1:69-75) .
- This Lf-mediated antimicrobial action has mainly been attributed to its iron deprivation capacity with bacteria (Arnold et al . (1977) Science 197:263-265; Law and Reiter (1977) J. Dairy Res . 44:595-599; Oram and Reiter (1968) Biochim . Biophys . Acta . 170:351-365) .
- iron is essential for microbial growth ( einberg, E.D. (1978) Microbiol . Rev.
- bacterial pathogens have developed specific iron uptake mechanisms.
- these mechanisms involve the synthesis and secretion of small compounds called siderophores which display high affinity for ferric iron (Felll) .
- Siderophores are capable of removing TF- or Lf-bound iron to form ferrisiderophore complexes which in turn are recognized by specific iron-repressible membrane receptors and internalized into the bacterium where the iron is released (Crosa, J.H. (1989) Microbiol . Rev. . 53:517-530) .
- This iron uptake mechanism has been described for many gram-negative bacterial species.
- Some gram-negative bacteria do not secrete detectable siderophores when grown in an iron-deficient environment but produce outer membrane proteins that bind directly and specifically to Tf or Lf, thereby allowing iron transport into the bacterial cell .
- Tf binding appears to be mediated by the activity of two proteins present in bacterial outer membranes, transferrin-binding protein 1 and 2 (Tbpl and Tbp2) (Gonzalez et al . (1990) Mol . Microbiol . 4 . : 1173-1179; Ogunnariwo and Schryvers (1990) Infect . Immun . 58 . : 2091-2097 ; Schryvers, A.B. (1989) J. Med . Microbiol . 29.: 121-130) ; Schryvers and Lee (1989) Can . J. Microbiol . 35:409-415; Schryvers and Morris (1988) Mol . Microbiol . 2:467-472) . Transferrin binding proteins tend to be highly specific for the transferrin of their natural host.
- Lbpl has been shown to be 46% identical to Tbpl (Comelissen et al . (1992) J. Bacteriol . 174:5788-5797) of the same gonococcal strain but only 18% identical to Tbp2 (Anderson et al . (1994) J. Bacteriol . 176:3162-3170) .
- the group A streptococcal M protein is considered to be one of the major virulence factors of this organism by virtue of its ability to impede attack by human phagocytes (Lancefield, R.C. (1962) J. Immunol . 89:307-313).
- the bacteria persist in the infected tissue until antibodies are produced against the M molecule.
- Type-specific antibodies to the M protein are able to reverse the antiphagocytic effect of the molecule and allow efficient clearance of the invading organism.
- M proteins are one of the key virulence factors of S . pyogenes, due to their involvement in mediating resistance to phagocytosis (Kehoe, M.A.
- group A streptococci the genes for M protein (emm) as well as a peptidase ⁇ scpA) and, if present, genes encoding M protein-related IgG- and IgA-binding proteins ( fcrA and enn, respectively) are clustered on the chromosome (Haanes et al . (1992) J " . Bacteriol . 174:4967-4976; Hollingshead et al . (1993) Mol . Microbiol . 8:707-717; Podbielski, A. (1993) Mol . Gen . Genet . 237:287-300). Expression of these virulence-associated surface proteins is co-regulated at the level of transcription by the protein Mga (which stands for multigene regulator of group A
- Mga is a part of a crucial regulatory system in GAS, possibly functioning as a second component in a two-component regulatory system.
- Vaccination is one approach to enhance resistance of the mammary gland to new infection and reduce clinical severity of the disease.
- Previous studies have shown that primary infection with S . uberis can considerably reduce the rate of infection following a second challenge with the same strain (Hill, A.W. (1988) Res . Vet . Sci . 44:386-387).
- Local vaccination with killed S . uberis protects the bovine mammary gland against intramammary challenge with the homologous strain (Finch et al . (1994) Jnfect. Immun . 62.:3599-3603) .
- subcutaneous vaccination with live S . uberis has been shown to cause a dramatic modification of the pathogenesis of mastitis with the same strain (Hill et al .
- the present invention is based on the discovery of a bovine lactoferrin (bLF) binding protein (bLbp) from S . uberis, and the characterization thereof.
- bLF-binding protein, immunogenic fragments and analogs thereof, and/or chimeric proteins including the same can be used, either alone or in combination with other antigens, in novel subunit vaccines to provide protection from bacterial infection in mammalian subj ects .
- the subject invention is directed to an isolated, immunogenic S . uberis bLF-binding protein, as well as a nucleic acid molecule comprising a coding sequence for an immunogenic S. uberis bLF-binding protein.
- the invention is directed to recombinant vectors including the same, host cells transformed with these vectors and methods of recombinantly producing S. uberis bLF-binding proteins .
- the subject invention is directed to vaccine compositions comprising a pharmaceutically acceptable vehicle and an immunogenic S . uberis bLF-binding protein.
- the present invention is directed to methods of treating or preventing S . uberis infections, such as mastitis, in a mammalian subject. The method comprises administering to the subject a therapeutically effective amount of the above vaccine compositions.
- the invention pertains to methods of producing vaccine compositions comprising (a) providing an immunogenic S . uberis bLF- binding protein; and (b) combining the protein with a pharmaceutically acceptable vehicle.
- the invention is directed to antibodies against the S. uberis bLF- binding proteins .
- the invention is directed to methods of detecting S . uberi s antibodies in a biological sample comprising:
- the invention is directed to an immunodiagnostic test kit for detecting S . uberis infection.
- the test kit comprises a S . uberi s bLF-binding protein and instructions for conducting the immunodiagnostic test.
- the invention is directed to an isolated S . uberis Mga protein, as well as a nucleic acid molecule comprising a coding sequence for the same .
- Figure 1 is a restriction enzyme map of Ibp and shows progressive deletions and a summary of bLf binding data.
- Open boxes (p region) represent 5'- sequences containing promoter and ribosome binding sites, shaded boxes (s region) represent Ibp sequences encoding the signal peptides, and hatched boxes represent the Ibp sequences coding for the mature or truncated proteins.
- RI and R201 (R represents residue) indicate the first codon of the mature protein in pLBP5 and the truncated protein in pTP51, respectively. Other numbers indicate the last codon of each protein. Restriction sites are present on the top of the Ibp . The bLf binding ability of each clone is shown on the right.
- Figures 2A-2C depict the nucleotide sequence and deduced amino acid sequence of S . uberis bovine Lbp . Nucleotides and amino acids are numbered on the right of the sequences. The deduced amino acid sequence is shown in the single-letter code below the nucleotide sequence. Two possible ATG start codons at positions 232 and 262, and the TAA stop codon at 1915, are shown in bold. Two putative -35 and -10 promoter sequences and Shine-Dalgarno sequences (SD) are indicated. A putative rho- independent transcription terminator (T) is underlined.
- the double underline shows the presence of a putative signal peptide at the N-terminus of the ORF .
- the C-terminal hydrophobic trans-membrane domain is indicated by italics and the nearby surface anchor motif is shown by italics and double underline.
- the central repeated amino acid sequences are indicated by the letters A, B, and C.
- Figure 3 shows profiles of the secondary structures, charged residues and hydrophobicity of Lbp.
- the deduced amino acid sequence of Lbp was analyzed with the Novotny-Auffray algorithm. Plots marked Turn, Beta, and Alpha indicate the potential for beta turn-random coil, beta sheet, and alpha helix formation, respectively.
- the +/- plot shows regions of the molecule with net positive (upper) and negative (lower) charges.
- the hydrophobicity (Hydro) plot shows the hydrophobic regions of the protein. The positions of the amino acids are shown on the horizontal axis.
- FIG. 4 depicts the construction of pMGA14F from pLBP5i and pMGA14.
- Plasmid pMGA14F was generated by inserting the 1.5 kb Sphl -Nhel fragment of pLBP5i into the Sphl and N el sites of pMGA14.
- Lines indicate S . uberis D ⁇ A, while the box represents the multiple cloning sites of vector pTZ18R.
- the probe fragments used for Southern or Northern blot experiments are indicated by the hatched bars.
- the arrows indicate the locations of the open reading frames of lbp, mga ' and mga .
- Figures 5A-5D show the nucleotide sequence of mga and deduced amino acid sequence of Mga, as well as the ORFs downstream of mga . Nucleotides and amino acids are numbered on the right of the sequences. The deduced amino acid sequence is shown in the single-letter code below the nucleotide sequence. Possible ATG start codons are shown in bold and the stop codons are indicated by "*”. A putative -35 and -10 promoter sequence and Shine-Dalgarno sequence (SD) are indicated.
- Figure 6 shows the probes used in hybridization analysis, as well as the structure of Lbp (on the top) , constructed from the DNA sequence analysis. The signal peptide, proline rich region and transmembrane domain are indicated by S, Pro and TM respectively. The A, B and C repeat regions are also shown. Probes used in hybridization are indicated by the hatched bars below the map.
- Figure 7 shows the time course of 125 I-bLf binding to S . uberis . IO 9 bacteria were incubated with 6.9 nm 125 I-bLf in 0.2 ml of PBS-1% BSA. At time intervals indicated, bacteria were pelleted and the amount of cell associated 125 I-bLf was determined.
- Figure 8 depicts the results of a competition binding assay using bLf (33% iron- saturated) as radiolabelled ligand and competitor. Percentage binding values were calculated as percentage of 125 I-bLf binding in the presence of increasing amounts of unlabelled bLf to bacteria suspended in PBS-1% BSA in the absence of unlabelled bLf.
- Figure 9 shows the influence of iron chelators on the expression of lactoferrin-binding by S . uberis .
- Cells grown in THB-YE with or without EDDA, dipyridyl or desferrioxamine mesylate were incubated with 6.9 nM 15 I-bLf in 0.2 ml of PBS-1% BSA at room temperature for 2 h. After three washes, cell-bound radioactivity was determined.
- Figure 10 shows the physical map of the recombinant plasmid used to express the Lbp in Example 3.
- the plasmid pLBP5 contains 3.7 kb of S. uberis- derived kDNA, in the vector pTZ18R.
- the plasmid pGH- LBP was constructed by subcloning an Sphl -Rsal fragment from pLBP5 into vector pGH433.
- P tac indicates the location of the tac promoter.
- the Lbp gene is shown by the arrows labelled as lbp .
- Figure 11 shows inhibition of recombinant bLf-binding protein on 125 I -labelled bLf binding to S . uberis .
- Increasing amounts of a mixture of supernatant (sup.) and whole cell lysate (with equal volume) of E. coli pLBP5 (•) or E. coli pTZ18R (O) were mixed with IO 9 cells and incubated with 0.69 nM 125 I-bLf in 0.2 ml volumes. Inhibition values were calculated as relative percentage of bLf binding to bacteria suspended in
- lactoferrin-binding protein intends a protein or a nucleotide sequence, respectively, which is derived from an S . uberis lbp gene.
- the nucleotide sequence of a representative S . uberis lbp gene, and the corresponding amino acid sequence of an LF-binding protein encoded by this gene, are depicted in Figures 2A-2C (SEQ ID NOS:l-2).
- an LF-binding protein as defined herein is not limited to the depicted sequence as several subtypes of S .
- uberis are known and variations in LF- binding proteins will occur between strains of S . uberi s .
- the derived protein or nucleotide sequences need not be physically derived from the gene described above, but may be generated in any manner, including for example, chemical synthesis, isolation (e.g., from S . uberis) or by recombinant production, based on the information provided herein. Additionally, the term intends proteins having amino acid sequences substantially homologous (as defined below) to contiguous amino acid sequences encoded by the genes, which display immunological and/or lactoferrin-binding activity.
- nucleotide fragments of the gene that include at least about 8 contiguous base pairs, more preferably at least about 10-20 contiguous base pairs, and most preferably at least about 25 to 50 or more contiguous base pairs of the gene. Such fragments are useful as probes and in diagnostic methods, discussed more fully below.
- the terms also include those forms possessing, as well as lacking, the signal sequence, as well as the nucleic acid sequences coding therefor. Additionally, the term intends forms of LF-binding protein which lack the membrane anchor region, and nucleic acid sequences encoding such deletions. Such deletions may be desirable in systems that do not provide for secretion of the protein. Furthermore, an LF-binding domain, found within about the N-terminal 200 codons, may or may not be present. Thus, for example, if the Lf binding protein will be used to purify LF, the LF-binding domain will generally be retained. If the protein is to be used in vaccine compositions, immunogenic epitopes which may or may not include the LF-binding domain, will be present.
- the terms also include proteins in neutral form or in the form of basic or acid addition salts depending on the mode of preparation.
- Such acid addition salts may involve free amino groups and basic salts may be formed with free carboxyls.
- the proteins may be modified by combination with other biological materials such as lipids (both those occurring naturally with the molecule or other lipids that do not destroy immunological activity) and saccharides, or by side chain modification, such as acetylation of amino groups, phosphorylation of hydroxyl side chains, oxidation of sulfhydryl groups, glycosylation of amino acid residues, as well as other modifications of the encoded primary sequence.
- side chain modification such as acetylation of amino groups, phosphorylation of hydroxyl side chains, oxidation of sulfhydryl groups, glycosylation of amino acid residues, as well as other modifications of the encoded primary sequence.
- the term therefore intends deletions, additions and substitutions to the sequence, so long as the polypeptide functions to produce an immunological response as defined herein.
- amino acids are generally divided into four families: (1) acidic -- aspartate and glutamate; (2) basic -- lysine, arginine, histidine;
- mastitis is meant an inflammation of the mammary gland in mammals, including in cows, ewes, goats, sows, mares, and the like, caused by the presence of S . uberis .
- the infection manifests itself by the infiltration of phagocytic cells in the gland.
- mastitis 4 clinical types are recognized: (1) peracute, associated with swelling, heat, pain, and abnormal secretion in the gland and accompanied by fever and other signs of systemic disturbance, such as marked depression, rapid weak pulse, sunken eyes, weakness and complete anorexia; (2) acute, with changes in the gland similar to those above but where fever, anorexia and depression are slight to moderate; (3) subacute, where no systemic changes are displayed and the changes in the gland and its secretion are less marked: and (4) subclinical, where the inflammatory reaction is detectable only by standard tests for mastitis.
- Standard tests for the detection of mastitis include but are not limited to, the California Mastitis Test, the Wisconsin Mastitis Test, the Nagase test, the electronic cell count and somatic cell counts used to detect a persistently high white blood cell content in milk.
- a somatic cell count of about 300,000 to about 500,000 cells per ml or higher, in milk will indicate the presence of infection.
- a vaccine is considered effective in the treatment and/or prevention of mastitis when, for example, the somatic cell count in milk is retained below about 500,000 cells per ml.
- nucleic acid molecule is a nucleic acid molecule separate and discrete from the whole organism with which the molecule is found in nature; or a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences (as defined below) in association therewith.
- subunit vaccine composition is meant a composition containing at least one immunogenic polypeptide, but not all antigens, derived from or homologous to an antigen from a pathogen of interest. Such a composition is substantially free of intact pathogen cells or particles, or the lysate of such cells or particles.
- a “subunit antigen composition” is prepared from at least partially purified (preferably substantially purified) immunogenic polypeptides from the pathogen, or recombinant analogs thereof.
- a subunit antigen composition can comprise the subunit antigen or antigens of interest substantially free of other antigens or polypeptides from the pathogen.
- epitope refers to the site on an antigen or hapten to which specific B cells and/or T cells respond.
- the term is also used interchangeably with "antigenic determinant” or "antigenic determinant site.”
- Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
- an "immunological response" to a composition or vaccine is the development in the host of a cellular and/ or antibody-mediated immune response to the composition or vaccine of interest.
- an "immunological response” includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells and/or ⁇ T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest.
- the host will display either a therapeutic or protective immunological response such that resistance of the mammary gland to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered somatic cell count in milk from the infected quarter.
- immunogenic protein or polypeptide refer to an amino acid sequence which elicits an immunological response as described above.
- An "immunogenic" protein or polypeptide, as used herein, includes the full-length sequence of the LF- binding protein, with or without the signal sequence, membrane anchor domain and/or LF-binding domain, analogs thereof, or immunogenic fragments thereof.
- immunogenic fragment is meant a fragment of an LF- binding protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epi tope Mapping Protocols in Methods in Molecular Biology, Vol.
- linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports.
- Such techniques are known in the art and described in, e.g., U.S. Patent No. 4,708,871; Geysen et al . (1984) Proc . Natl . Acad . Sci . USA 81:3998-4002; Geysen et al . (1986) Molec . Immunol .
- conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2 -dimensional nuclear magnetic resonance. See, e.g., Epi tope Mapping Protocols, supra .
- Immunogenic fragments for purposes of the present invention, will usually include at least about 3 amino acids, preferably at least about 5 amino acids, more preferably at least about 10-15 amino acids, and most preferably 25 or more amino acids, of the Lbp molecule. There is no critical upper limit to the length of the fragment, which could comprise nearly the full-length of the protein sequence, or even a fusion protein comprising two or more epitopes of Lbp.
- Native proteins or polypeptides refer to proteins or polypeptides isolated from the source in which the proteins naturally occur.
- Recombinant polypeptides refer to polypeptides produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide.
- Synthetic polypeptides are those prepared by chemical synthesis.
- a “vector” is a replicon, such as a plasmid, phage, or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
- a DNA "coding sequence” or a "nucleotide sequence encoding" a particular protein is a DNA sequence which is transcribed and translated into a polypeptide in vi tro or in vivo when placed under the control of appropriate regulatory elements. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus.
- a coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences.
- a transcription termination sequence will usually be located 3 ' to the coding sequence .
- control elements refers collectively to promoters, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell. Not all of these control sequences need always be present in a recombinant vector so long as the desired gene is capable of being transcribed and translated.
- operably linked refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function.
- control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence.
- the control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof.
- intervening untranslated yet transcribed sequences can be present between a promoter and the coding sequence and the promoter can still be considered “operably linked" to the coding sequence.
- RNA polymerase directs the transcription of a coding sequence in a cell when RNA polymerase will bind the promoter and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.
- a "host cell” is a cell which has been transformed, or is capable of transformation, by an exogenous nucleic acid molecule.
- a cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane.
- Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
- the exogenous DNA may be maintained on an episomal element, such as a plasmid.
- a stably transformed cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eucaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the exogenous DNA.
- homology refers to the percent identity between two polynucleotide or two polypeptide moieties.
- the correspondence between the sequence from one moiety to another can be determined by techniques known in the art. For example, homology can be determined by a direct comparison of the sequence information between two polypeptide molecules by aligning the sequence information and using readily available computer programs such as ALIGN, Dayhoff, M.O. (1978) in Atlas of Protein Sequence and Structure 5:Suppl. 3, National biomedical Research Foundation, Washington, DC. Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments.
- Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules, as determined using the methods above.
- substantially homologous also refers to sequences showing complete identity to the specified DNA or polypeptide sequence.
- DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al . , supra ; DNA Cloning, supra ; Nucleic Acid Hybridization, supra .
- the term "functionally equivalent” intends that the amino acid sequence of an LF-binding protein is one that will elicit a substantially equivalent or enhanced immunological response, as defined above, as compared to the response elicited by an LF-binding protein having identity with the reference LF-binding protein, or an immunogenic portion thereof.
- a "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature.
- the heterologous region encodes a bacterial gene
- the gene will usually be flanked by DNA that does not flank the bacterial gene in the genome of the source bacteria.
- Another example of the heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene) . Allelic variation or naturally occurring mutational events do not give rise to a heterologous region of DNA, as used herein.
- a "biological sample” refers to a sample of tissue or fluid isolated from a subject, including but not limited to, for example, blood, plasma, serum, fecal matter, urine, bone marrow, bile, spinal fluid, lymph fluid, samples of the skin, external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, organs, biopsies and also samples of in vi tro cell culture constituents including but not limited to conditioned media resulting from the growth of cells and tissues in culture medium, e.g., recombinant cells, and cell components .
- label and “detectable label” refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorescers, chemiluminescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chromophores , dyes, metal ions, metal sols, ligands (e.g., biotin or haptens) and the like.
- fluorescer refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range.
- labels which may be used under the invention include fluorescein, rhodamine, dansyl , umbelliferone, Texas red, luminol , NADPH and - ⁇ - galactosidase .
- a single ORF of 1683 bp depicted as residues 232-1914, inclusive of Figures 2A-2C (SEQ ID N0S:l-2), encoding 561 amino acid residues, gives rise to two protein species able to bind bovine lactoferrin, having molecular weights of 76 kDa and 165 kDa, respectively.
- the 165 kDa protein is likely a dimer of the 76 kDa protein since urea treatment results in a single band and Northern blot analysis shows only one major transcript in S . uberis, as well as in recombinant E. coli transformed with a construct encoding the LF-binding protein.
- S. uberis bovine LF-binding protein includes a putative N-terminal signal peptide of about 50 amino acids (if translation starts at the first ATG codon shown in Figure 2A) .
- the full-length bovine LF- binding protein depicted, including the signal sequence is found at amino acid positions 1-561, inclusive, (encoded by nucleotide positions 232-1914, inclusive) of Figures 2A-2C (SEQ ID NOS: 1-2).
- the mature protein, lacking the signal peptide is found at amino acid positions 52-561, inclusive, (nucleotide positions 445-1914, inclusive) of Figures 2A-2C.
- a membrane anchor motif at the C-terminus is also present, as indicated in Figures 2A-2C (SEQ ID N0S:1- 2) .
- a bovine Lf binding domain is present in a 200 codon N-terminal region of the molecule. The protein appears to lack disulfide bridges.
- the binding of 125 1 -bLf to S. uberis was time-dependent and displaceable by unlabelled bLf.
- Apo-bLf inhibits 125 i- bLf binding as effectively as iron-saturated bLf.
- Bovine transferrin, human lactoferrin and human transferrin do not interfere with bLf binding.
- the Scatchard plot is linear and approximately 7800 binding sites are expressed by each bacterial cell, with an affinity of 1.0 x IO "7 M. Reduced iron availability does not significantly modify the saturation of S . uberis by bLf.
- the bLf binding protein described herein is lactoferrin species- specific, in that human Lf does not appear to effectively block the binding of bovine Lf .
- the Lf binding protein of S . uberis differs from the transferrin receptors of Haemophilus and Neisseria sp . , which consist of two distinct transferrin-binding proteins, termed Tbpl and Tbp2 , which range in molecular weight from 68 to 105 kDa depending on the strain.
- Tbpl and Tbp2 transferrin-binding proteins
- the bovine Lf receptor of S . aureus consists of two distinct bLf binding proteins with estimated molecular weights of 92 and 67 kDa (Naidu et al . (1991) J " . Dairy Sci . 74:1218-1226) and therefore appears to be different from the receptor described herein.
- streptococcal LF-binding protein described herein appears to be different from the S. aureus human Lf binding protein, an approximately 450 kDa protein which, under reducing SDS-PAGE gel conditions, resolves into two components of 67 and 62 kDa.
- S . uberis bLf binding protein Analysis of the primary and secondary structure of the S . uberis bLf binding protein suggests that it is an M-like protein.
- a gene homologous to the group A streptococcal mga a positive regulator of M and M-like proteins, has been found in the upstream adjacent region of lbp .
- Southern blot analysis reveals that mga is present in all S. uberis strains tested that contained the lbp .
- the sequence of S . uberis mga and the protein product therefrom is presented in Figures 5A- 5D (SEQ ID NOS:3-12) .
- the deduced gene product, Mga is comprised of 499 amino acid residues with a calculated molecular weight of 58,454 Da.
- the N-terminus of Mga lacks the features of a signal peptide, suggesting that it is a cytoplasmic protein.
- Preceding the start codon of mga is a putative ribosome binding site AGGAGA. Sequences resembling the -35 and -10 promoter motifs have also been identified, as shown in Figures 5A-5D (SEQ ID NOS: 3-12) .
- S . uberis LF-binding protein immunogenic fragments thereof or chimeric proteins including the same
- S . uberis LF-binding protein can be provided in subunit vaccine compositions to treat or prevent bacterial infections caused by S . uberis, including mastitis in mammals, such as in bovine, equine, ovine and goat species.
- the proteins and fragments thereof, antibodies thereto, and genes coding therefor can be used as diagnostic reagents to detect the presence of infection in a mammalian subject.
- the genes encoding the proteins can be cloned and used to design probes to detect and isolate homologous genes in other bacterial strains.
- fragments comprising at least about 15-20 nucleotides, more preferably at least about 20-50 nucleotides, and most preferably about 60-100 or more nucleotides, will find use in these embodiments.
- the S . uberis LF-binding proteins also find use in purifying bovine LFs from streptococcal species and from recombinant host cells expressing the same.
- S . uberis Lf binding proteins can be used in vaccine compositions either alone or in combination with other bacterial, fungal, viral or protozoal antigens. These antigens can be provided separately or even as fusion proteins comprising one or more epitopes of an LF-binding protein fused to one or more of these antigens.
- other immunogenic proteins from S . uberis such as the CAMP factor, hyaluronic acid capsule, hyaluronidase, R-like protein and plasminogen activator, can be administered with the LF-binding protein.
- immunogenic proteins from other organisms involved in mastitis such as from the genera Staphylococcus , Corynebacterium, Pseudomonas, Nocardia, Clostridium, Mycobacterium, Mycoplasma, Pasteurella, Prototheca, other streptococci, coliform bacteria, as well as yeast, can be administered along with the bLF-binding proteins described herein to provide a broad spectrum of protection.
- zooepidemicus Corynebacterium pyogenes, Pseudomonas aeruginosa, Nocardia asteroides, Clostridium perfringens, Escherichia coli , Enterobacter aerogenes and Klebsiella spp. can be provided along with the bLF-binding proteins of the present invention.
- LF-binding proteins can be isolated directly from bacteria which express the same. This is generally accomplished by first preparing a crude extract which lacks cellular components and several extraneous proteins. The desired proteins can then be further purified i.e. by column chromatography, HPLC, immunoadsorbent techniques or other conventional methods well known in the art .
- the proteins can be recombinantly produced as described herein.
- these recombinant products can take the form of partial protein sequences, full-length sequences, precursor forms that include signal sequences, mature forms without signals, or even fusion proteins (e.g., with an appropriate leader for the recombinant host, or with another subunit antigen sequence for Streptococcus or another pathogen) .
- the lbp genes of the present invention can be isolated based on the ability of the protein products to bind LF, using LF-binding assays as described below.
- gene libraries can be constructed and the resulting clones used to transform an appropriate host cell. Colonies can be pooled and screened for clones having LF-binding activity. Colonies can also be screened using polyclonal serum or monoclonal antibodies to the LF-binding protein.
- oligonucleotide probes which contain the codons for a portion of the determined amino acid sequences can be prepared and used to screen genomic or cDNA libraries for genes encoding the subject proteins.
- the basic strategies for preparing oligonucleotide probes and DNA libraries, as well as their screening by nucleic acid hybridization, are well known to those of ordinary skill in the art. See, e.g., DNA Cloning: Vol. I, supra; Nucleic Acid Hybridization, supra; Oligonucleotide Synthesis, supra; Sambrook et al . , supra .
- a clone from the screened library has been identified by positive hybridization, it can be confirmed by restriction enzyme analysis and DNA sequencing that the particular library insert contains an LF-binding protein gene or a homolog thereof.
- the genes can then be further isolated using standard techniques and, if desired, PCR approaches or restriction enzymes employed to delete portions of the full-length sequence.
- genes can be isolated directly from bacteria using known techniques, such as phenol extraction and the sequence further manipulated to produce any desired alterations. See, e.g., Sambrook et al . , supra, for a description of techniques used to obtain and isolate DNA.
- DNA sequences encoding the proteins of interest can be prepared synthetically rather than cloned.
- the DNA sequences can be designed with the appropriate codons for the particular amino acid sequence. In general, one will select preferred codons for the intended host if the sequence will be used for expression.
- the complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) Nature 292:756; Nambair et al . (1984) Science 223 :1299; Jay et al. (1984) J. Biol . Chem . 259:6311.
- coding sequences for the desired proteins can be cloned into any suitable vector or replicon.
- Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice.
- Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage ⁇ (E. coli) , pBR322 (E. coli ) , pACYC177 (E. coli) , pKT230 (gram-negative bacteria) , pGV1106 (gram-negative bacteria) , pLAFRl (gram-negative bacteria) , pME290
- the gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements) , so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction.
- the coding sequence may or may not contain a signal peptide or leader sequence. If a signal sequence is included, it can either be the native, homologous sequence, or a heterologous sequence.
- the signal sequence for S. uberis LF-binding protein shown in Figure 2A
- Leader sequences can be removed by the host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397. Other regulatory sequences may also be desirable which allow for regulation of expression of the protein sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.
- the control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.
- Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are described in, e.g., Sambrook et al . , supra; DNA Cloning, supra ; Nucleic Acid Hybridization, supra . The expression vector is then used to transform an appropriate host cell.
- a number of mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (ATCC) , such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS) , human hepatocellular carcinoma cells (e.g., Hep G2), Madin-Darby bovine kidney (“MDBK”) cells, as well as others.
- ATCC American Type Culture Collection
- CHO Chinese hamster ovary
- HeLa cells HeLa cells
- baby hamster kidney (BHK) cells baby hamster kidney (BHK) cells
- COS monkey kidney cells
- MDBK Madin-Darby bovine kidney
- bacterial hosts such as E. coli , Bacillus subtilis, and Streptococcus spp . , will find use with the present expression constructs.
- Yeast hosts useful in the present invention include inter alia, Saccharomyces cerevisi
- Insect cells for use with baculovirus expression vectors include, inter alia, Aedes aegypti , Autographa californica, Bombyx ori , Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni .
- the proteins of the present invention are produced by culturing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed. The protein is then isolated from the host cells and purified. If the expression system secretes the protein into the growth media, the protein can be purified directly from the media. If the protein is not secreted, it is isolated from cell lysates. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.
- the proteins of the present invention may also be produced by chemical synthesis such as solid phase peptide synthesis, using known amino acid sequences or amino acid sequences derived from the DNA sequence of the genes of interest . Such methods are known to those skilled in the art. See, e.g., J. M. Stewart and J. D. Young, Solid Phase Peptide
- LF-binding proteins of the present invention can be used to produce antibodies, both polyclonal and monoclonal.
- a selected mammal e.g., mouse, rabbit, goat, horse, etc.
- Serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al . (1985) J " . Chrom . 348 :363-370.
- serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures .
- Monoclonal antibodies to the LF-binding proteins and to the fragments thereof can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies by using hybridoma technology is well known.
- Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al . , Hybridoma Techniques (1980);
- Panels of monoclonal antibodies produced against the LF-binding protein, or fragment thereof, can be screened for various properties; i.e., for isotype, epitope, affinity, etc.
- Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the individual antigens which they are directed against . Both polyclonal and monoclonal antibodies can also be used for passive immunization or can be combined with subunit vaccine preparations to enhance the immune response. Polyclonal and monoclonal antibodies are also useful for diagnostic purposes .
- LF-binding proteins of the present invention can be formulated into vaccine compositions, either alone or in combination with other antigens, for use in immunizing subjects as described below. Methods of preparing such formulations are described in, e.g., Remington ' s Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 18 Edition, 1990.
- the vaccines of the present invention are prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in or suspension in liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles.
- the active immunogenic ingredient is generally mixed with a compatible pharmaceutical vehicle, such as, for example, water, saline, dextrose, glycerol , ethanol, or the like, and combinations thereof.
- a compatible pharmaceutical vehicle such as, for example, water, saline, dextrose, glycerol , ethanol, or the like, and combinations thereof.
- the vehicle may contain minor amounts of auxiliary substances such as wetting or emulsifying agents and pH buffering agents.
- Adjuvants which enhance the effectiveness of the vaccine may also be added to the formulation.
- Adjuvants may include for example, muramyl dipeptides, avridine, aluminum hydroxide, dimethyldioctadecyl ammonium bromide (DDA) , oils, oil-in-water emulsions, saponins, cytokines, and other substances known in the art .
- DDA dimethyldioctadecyl ammonium bromide
- the Lf binding protein may be linked to a carrier in order to increase the immunogenicity thereof.
- Suitable carriers include large, slowly metabolized macromolecules such as proteins, including serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, and other proteins well known to those skilled in the art; polysaccharides, such as sepharose, agarose, cellulose, cellulose beads and the like; polymeric amino acids such as polyglutamic acid, polylysine, and the like; amino acid copolymers; and inactive virus particles .
- proteins including serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, and other proteins well known to those skilled in the art
- polysaccharides such as sepharose, agarose, cellulose, cellulose beads and the like
- polymeric amino acids such as polyglutamic acid, polylysine, and the like
- amino acid copolymers amino acid copo
- the LF-binding proteins may be used in their native form or their functional group content may be modified by, for example, succinylation of lysine residues or reaction with Cys-thiolactone .
- a sulfhydryl group may also be incorporated into the carrier (or antigen) by, for example, reaction of amino functions with 2-iminothiolane or the N-hydroxysuccinimide ester of 3- (4-dithiopyridyl propionate.
- Suitable carriers may also be modified to incorporate spacer arms (such as hexamethylene diamine or other bifunctional molecules of similar size) for attachment of peptides.
- Suitable carriers for the LF-binding proteins of the present invention include VP6 polypeptides of rotaviruses, or functional fragments thereof, as disclosed in U.S. Patent No. 5,071,651. Also useful is a fusion product of a viral protein and the subject immunogens made by methods disclosed in
- Still other suitable carriers include cells, such as lymphocytes, since presentation in this form mimics the natural mode of presentation in the subject, which gives rise to the immunized state.
- the proteins of the present invention may be coupled to erythrocytes, preferably the subject's own erythrocytes. Methods of coupling peptides to proteins or cells are known to those of skill in the art.
- the LF-binding proteins (or complexes thereof) may be formulated into vaccine compositions in either neutral or salt forms.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the active polypeptides) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
- Salts formed from free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic
- Vaccine formulations will contain a "therapeutically effective amount" of the active ingredient, that is, an amount capable of eliciting an immune response in a subject to which the composition is administered.
- a "therapeutically effective amount” would preferably be an amount that enhances resistance of the mammary gland to new infection and/or reduces the clinical severity of the disease. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered somatic cell count in milk from the infected quarter.
- the ability of the composition to retain or bring the somatic cell count (SCC) in milk below about 500,000 cells per ml, the threshold value set by the International Dairy Federation, above which, animals are considered to have clinical mastitis, will be indicative of a therapeutic effect.
- the exact amount is readily determined by one skilled in the art using standard tests.
- the LF- binding protein concentration will typically range from about 1% to about 95% (w/w) of the composition, or even higher or lower if appropriate.
- 20 to 500 ⁇ g of active ingredient per ml of injected solution should be adequate to raise an immunological response when a dose of 1 to 3 ml per animal is administered.
- the vaccine is generally administered parenterally, usually by intramuscular injection. Other modes of administration, however, such as subcutaneous, intraperitoneal and intravenous injection, are also acceptable.
- the quantity to be administered depends on the animal to be treated, the capacity of the animal's immune system to synthesize antibodies, and the degree of protection desired.
- Effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.
- the subject is immunized by administration of the vaccine in at least one dose, and preferably two doses.
- the animal may be administered as many doses as is required to maintain a state of immunity to infection.
- Additional vaccine formulations which are suitable for other modes of administration include suppositories and, in some cases, aerosol, intranasal, oral formulations, and sustained release formulations.
- the vehicle composition will include traditional binders and carriers, such as, polyalkaline glycols, or triglycerides .
- binders and carriers such as, polyalkaline glycols, or triglycerides .
- Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w) , preferably about 1% to about 2%.
- Oral vehicles include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium, stearate, sodium saccharin cellulose, magnesium carbonate, and the like.
- oral vaccine compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and contain from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%.
- Intranasal formulations will usually include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function.
- Diluents such as water, aqueous saline or other known substances can be employed with the subject invention.
- the nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride.
- a surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.
- Controlled or sustained release formulations are made by incorporating the protein into carriers or vehicles such as liposomes, nonresorbable impermeable polymers such as ethylenevinyl acetate copolymers and Hytrel ® copolymers, swellable polymers such as hydrogels, or resorbable polymers such as collagen and certain polyacids or polyesters such as those used to make resorbable sutures.
- carriers or vehicles such as liposomes, nonresorbable impermeable polymers such as ethylenevinyl acetate copolymers and Hytrel ® copolymers, swellable polymers such as hydrogels, or resorbable polymers such as collagen and certain polyacids or polyesters such as those used to make resorbable sutures.
- the LF-binding proteins can also be delivered using implanted mini-pumps, well known in the art.
- the LF-binding proteins of the instant invention can also be administered via a carrier virus which expresses the same.
- Carrier viruses which will find use with the instant invention include but are not limited to the vaccinia and other pox viruses, adenovirus, and herpes virus.
- vaccinia virus recombinants expressing the novel proteins can be constructed as follows. The DNA encoding the particular protein is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK) . This vector is then used to transfect cells which are simultaneously infected with vaccinia.
- TK thymidine kinase
- Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the instant protein into the viral genome.
- the resulting TK " recombinant can be selected by culturing the cells in the presence of 5- bromodeoxyuridine and picking viral plaques resistant thereto .
- An alternative route of administration involves gene therapy or nucleic acid immunization.
- nucleotide sequences (and accompanying regulatory elements) encoding the subject LF-binding proteins can be administered directly to a subject for in vivo translation thereof.
- gene transfer can be accomplished by transfecting the subject's cells or tissues ex vivo and reintroducing the transformed material into the host.
- DNA can be directly introduced into the host organism, i.e., by injection (see International Publication No.
- Liposome-mediated gene transfer can also be accomplished using known methods. See, e.g., Hazinski et al. (1991) Am. J. Respir. Cell Mol . Biol . 4:206- 209; Brigham et al . (1989) Am. J. Med . Sci . 298:278- 281; Canonico et al . (1991) Clin . Res . 39:219A; and Nabel et al . (1990) Science 249:1285-1288.
- Targeting agents such as antibodies directed against surface antigens expressed on specific cell types, can be covalently conjugated to the liposomal surface so that the nucleic acid can be delivered to specific tissues and cells susceptible to infection.
- the LF-binding proteins of the present invention may also be used as diagnostics to detect the presence of reactive antibodies of S . uberis in a biological sample in order to determine the presence of S . uberis infection.
- the presence of antibodies reactive with LF-binding proteins can be detected using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays.
- Such assays include, but are not limited to, Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis ; immunoprecipitation, etc.
- the reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
- the aforementioned assays generally involve separation of unbound antibody in a liquid phase from a solid phase support to which antigen-antibody complexes are bound.
- Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates) ; polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like.
- a solid support is first reacted with a solid phase component (e.g., one or more LF- binding proteins) under suitable binding conditions such that the component is sufficiently immobilized to the support.
- a solid phase component e.g., one or more LF- binding proteins
- immobilization of the antigen to the support can be enhanced by first coupling the antigen to a protein with better binding properties.
- Suitable coupling proteins include, but are not limited to, macromolecules such as serum albumins including bovine serum albumin (BSA) , keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, and other proteins well known to those skilled in the art.
- molecules that can be used to bind the antigens to the support include polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and the like.
- Such molecules and methods of coupling these molecules to the antigens are well known to those of ordinary skill in the art. See, e.g., Brinkley, M.A. Bioconjugate Chem . (1992) 3:2-13; Hashida et al . , J. Appl . Biochem. (1984) 6.: 56-63; and Anjaneyulu and Staros, International J. of Peptide and Protein Res . (1987) 30:117-124.
- any non- immobilized solid-phase components are removed from the support by washing, and the support -bound component is then contacted with a biological sample suspected of containing ligand moieties (e.g., antibodies toward the immobilized antigens) under suitable binding conditions.
- a biological sample suspected of containing ligand moieties e.g., antibodies toward the immobilized antigens
- a secondary binder moiety is added under suitable binding conditions, wherein the secondary binder is capable of associating selectively with the bound ligand.
- the presence of the secondary binder can then be detected using techniques well known in the art. More particularly, an ELISA method can be used, wherein the wells of a microtiter plate are coated with an LF-binding protein.
- a biological sample containing or suspected of containing anti-LF- binding protein immunoglobulin molecules is then added to the coated wells. After a period of incubation sufficient to allow antibody binding to the immobilized antigen, the plate (s) can be washed to remove unbound moieties and a detectably labeled secondary binding molecule added. The secondary binding molecule is allowed to react with any captured sample antibodies, the plate washed and the presence of the secondary binding molecule detected using methods well known in the art.
- the presence of bound anti-LF-binding antigen ligands from a biological sample can be readily detected using a secondary binder comprising an antibody directed against the antibody ligands.
- a secondary binder comprising an antibody directed against the antibody ligands.
- a number of anti-bovine immunoglobulin (Ig) molecules are known in the art which can be readily conjugated to a detectable enzyme label, such as horseradish peroxidase, alkaline phosphatase or urease, using methods known to those of skill in the art.
- An appropriate enzyme substrate is then used to generate a detectable signal .
- competitive-type ELISA techniques can be practiced using methods known to those skilled in the art .
- Assays can also be conducted in solution, such that the LF-binding proteins and antibodies specific for those proteins form complexes under precipitating conditions.
- LF-binding proteins can be attached to a solid phase particle (e.g., an agarose bead or the like) using coupling techniques known in the art, such as by direct chemical or indirect coupling.
- the antigen-coated particle is then contacted under suitable binding conditions with a biological s ' ample suspected of containing antibodies for the LF-binding proteins.
- Cross-linking between bound antibodies causes the formation of particle-antigen-antibody complex aggregates which can be precipitated and separated from the sample using washing and/or centrifugation.
- the reaction mixture can be analyzed to determine the presence or absence of antibody- antigen complexes using any of a number of standard methods, such as those immunodiagnostic methods described above.
- an immunoaffinity matrix can be provided, wherein a polyclonal population of antibodies from a biological sample suspected of containing anti-LF-binding molecules is immobilized to a substrate.
- an initial affinity purification of the sample can be carried out using immobilized antigens.
- the resultant sample preparation will thus only contain anti-S. uberis moieties, avoiding potential nonspecific binding properties in the affinity support.
- a number of methods of immobilizing immunoglobulins (either intact or in specific fragments) at high yield and good retention of antigen binding activity are known in the art . Not being limited by any particular method, immobilized protein A or protein G can be used to immobilize immunoglobulins .
- labeled LF-binding proteins are contacted with the bound antibodies under suitable binding conditions. After any non-specifically bound antigen has been washed from the immunoaffinity support, the presence of bound antigen can be determined by assaying for label using methods known in the art .
- antibodies raised to the LF- binding proteins can be used in the above-described assays in order to detect the presence of antibodies to the proteins in a given sample. These assays are performed essentially as described above and are well known to those of skill in the art.
- kits can be provided in kits, with suitable instructions and other necessary reagents, in order to conduct immunoassays as described above.
- the kit can also contain, depending on the particular immunoassay used, suitable labels and other packaged reagents and materials (i.e. wash buffers and the like) . Standard immunoassays, such as those described above, can be conducted using these kits.
- S . uberis strain (su-1) from the American Type Culture Collection (ATCC 9927) was used for study. Bacteria were grown on base #2 sheep blood agar plates (PML Microbiologicals) at 37°C for 18 h. Iron- restricted conditions were achieved in Todd-Hewitt broth supplemented with 0.3% yeast extract (THB-YE) by the addition of 800 ⁇ M EDDA, 800 ⁇ M dipyridyl or 100 ⁇ M desferrioxamine mesylate. All of the iron chelators were obtained from Sigma.
- iron-binding proteins including bLf (from bovine milk) , bovine transferrin (bTf) , human lactoferrin (hLf) and human transferrin (hTf) , were purchased from Sigma in the most iron-free form available. Iron-saturated proteins and the apoproteins were prepared by methods described previously (Mazurier and Spik (1980) Biochim . Biophys . Acta 629:399-408) .
- Bovine Lf was iodinated by the lactoperoxidase method of Thorell and Johansson (1971) Biochim . Biophys . Acta 251: 363-368. Approximately 70 ⁇ g of bLf (33% iron-saturated) was used for iodination; 12S I-labelled protein was separated from free Na 125 I by chromatography on a Sephadex G-25 column. The labelled protein was aliquoted and stored at -70°C until use. Lactoperoxidase was purchased from Boehringer-Mannheim; and Na 125 I from Amersham.
- the binding assays were performed as described (Naidu et al . (1990) J. din . Microbiol .
- PBS phosphate-buffered saline
- BSA bovine serum albumin
- IO 9 bacteria in 0.1 ml of PBS-1% BSA were mixed and incubated with 0.1 ml of 125 I-bLf solution (6.9 nM in PBS-1 % BSA) for periods of 5, 10, 15, 20, 25, 30, 60, 90, 120, 150 min at room temperature. Bacteria were pelleted and washed three times with 1 ml of ice- cold PBS containing 0.1% Tween 20. Radioactivity bound to the bacterial pellet was measured in a ⁇ - counter. In competitive binding experiments, IO 9 bacteria were mixed with 2 x 10 s cpm 125 I-bLf in the presence of serially-diluted unlabelled bLf and incubated at room temperature for 2 h.
- Proteinase K (Boehringer mannheim) treatment was carried out in 40 mM potassium phosphate buffer (pH 7.5), and the digestion was inhibited by the addition of phenylmethylsulfonyl fluoride (500 ⁇ g/ml) .
- the bacterial suspension (10 10 cell/ml) was incubated in a water bath for 1 h at each of the following temperatures: 50°C, 80°C and 100°C. Both enzyme and heat-treated cells were washed once in PBS and resuspended in PBS-1% BSA prior to the binding experiments .
- SDS-polyacrylamide gel electrophoresis of proteins was performed using the method described by Laemmli (Laemmli, U.K. (1970) Nature 227 : 680-685) . Samples were solubilized in sample buffer at 37°C for 30 min in the absence of 2- mercaptoethanol (non-reducing conditions) or at 100°C for 5 min in the presence of 1% 2-mercaptoethanol (reducing conditions) . Proteins were electrophoretically transferred to nitrocellulose membranes as recommended by the supplier (Bio-Rad) and blocked with TBS-1% BSA.
- 125 I-bLf was added to the membrane to a final concentration of 80 ng/ml in TBS-1% BSA and incubated at room temperature for 2 h. After three washes with TBS containing 0.05% Tween 20, the membrane was exposed to X-ray film for 24 h at room temperature. To compete the 125 I-bLf binding, the transferred membrane was incubated with 35 ⁇ g/ml of unlabelled bLf for 2 h before incubation with 125 I-bLf. Results Time-dependent binding of bLF to S . uberis .
- Inhibition values were calculated as relative percentage of bLf binding to bacteria suspended in PBS in the absence of any inhibitor.
- Bovine Lf binding to S. uberis was time and concentration dependent (demonstrated by the ability of the unlabelled ligand to compete for binding with 125 i- bLf) , indicating the existence of a limited number of binding receptors on the cell surface. Scatchard plot analysis estimated that there were 7800 bLf-binding sites/cell.
- S. aureus Lf receptors have been shown to bind lactoferrins from both human and bovine sources ( ⁇ aidu et al. (1990) J “ . Clin . Microbiol . 28: 2312-2319 ; ⁇ aidu et al. (1991) J “ . Med . Micrbiol . 34:323-328; ⁇ aidu et al. (1991) J “ . Dairy Sci . 74:1218-1226; ⁇ aidu et al . (1992) J “ . Med. Microbiol . 36:177-183).
- S uberis is exclusively a bovine pathogen
- aureus could not be blocked by human or bovine transferrin. Although the expression of most of the transferrin and lactoferrin receptors of Gram-negative bacteria such as N. meningi tidis and H. influenza is iron regulated, S . uberis receptor activity was not regulated by growth medium iron availability. The results are consistent with the findings of Modun et al . (1994) Infect . Immun . 62:3850-3858 and Rainard, P. (1992) FEMS Microbiol . Lett . 98:235-240 who showed that the binding of S. aureus to Tf and S. agalactiae to Lf was not regulated by iron.
- the lactoferrin-binding protein of S. uberis differs from the transferrin receptors of Haemophilus and Neisseria spp., which consist of two distinct transferrin-binding proteins, termed Tbpl and Tbp2 , which range in molecular weight from 68 to 105 kDa depending on the strain.
- Tbpl and Tbp2 two distinct transferrin-binding proteins, termed Tbpl and Tbp2 , which range in molecular weight from 68 to 105 kDa depending on the strain.
- the S . uberis Lbp is also different from the lactoferrin receptors of the mentioned two species.
- the bovine lactoferrin receptor of S. aureus consists of two distinct bLf-binding proteins with estimated molecular weights of 92 and 67 kDa (Naidu et al . (1991) J. Dairy Sci . 74: 1218-1226) and therefore appears to be different than the receptor described herein.
- streptococcal Lbp described here appears to be different from the S. aureus human lactoferrin-binding protein which is as an approximately 450 kDa protein which under reducing SDS-PAGE gel conditions resolves into two components of 67 and 62 kDa.
- Bacterial strains Bacterial strains, plasmids and media.
- S . uberis strains used are listed in Table 2 below. Bacteria were grown on base #2 sheep blood agar plates (PML Microbiologicals) at 37°C for 18 h, or in Todd-Hewitt broth supplemented with 0.3% yeast extract (THB-YE) at 37°C overnight. E. coli cells were grown in Luria broth or on Luria broth-agar plates. Ampicillin was used at 50 ⁇ g/ml for the growth of E. coli strains containing recombinant plasmids. The cloning vector used was pTZ18R (Mead et al. (1986) Protein Eng. 1:67-74).
- the 100 fold-concentrated culture supernatant of the recombinant E. coli was obtained by precipitation with 10% trichloroacetic acid (TCA) .
- PBS-1% BSA bovine serum albumin
- Serum against the recombinant Lbp of S . uberis was raised in rabbits by subcutaneous injection of 0.5 ml of TCA-precipitated culture supernatant of recombinant E. coli in complete Freund's adjuvant. Two subcutaneous boosts with the same amount of sample in incomplete Freund's adjuvant were given to each animal .
- Nonspecific binding was blocked by incubation in TBS (10 mM Tris-HCl, pH 7.5, 140 mM NaCl) -1% bovine serum albumin (BSA) . Blots were incubated with antibody diluted 1:200 in TBS-1% BSA at room temperature for 1 h. After three washes in TBS containing 0.05% Tween 20, seroreactive proteins were detected with goat anti-mouse (or rabbit) IgG coupled to alkaline phosphatase (Kirkegaard & Perry Laboratories, Inc.) at 1:5,000 in TBS-1% BSA. Alkaline phosphatase activity was detected using the Nitro Blue Tetrazolium-5-bromo- 4-chloro-3 -indolylphosphate toluidinium system as described by the supplier (Promega) .
- Plasmid DNA was purified as described by
- DNA fragments were isolated from agarose gels using a Gene Clean kit (Bio/can Scientific) .
- chromosomal DNA was prepared as previously described (Caparon and Scott (1987) Proc . Natl . Acad . Sci . USA 84.: 8677-8681) and partially digested with Sau3AI . Fragments of 2,000 to 5,000 bp were recovered following sucrose density gradient centrifugation (Sambrook et al . , supra) . The ends of these fragments were partially filled in with dGTP and dATP and ligated into pTZ18R which was cut with Sail and partially filled in with dTTP and dCTP . Transformation of E.
- coli DH5 ⁇ competent cells was carried out as recommended by the supplier (GIBCO BRL, Gaithersburg, Md) .
- transformants were replica-plated onto nitrocellulose discs (Schleicher & Schuell, Keene, NH) and lysed in chloroform vapor. Nonspecific binding was blocked by incubation with TBS-1% BSA. Membranes were further incubated with 125 I-bLf as described in Example 1.
- DNA sequences were determined by the dideoxy-chain termination method of Sanger et al . (1977) Proc . Natl . Acad . Sci . USA 74:5463-5467 on double-stranded plasmid templates by using a T7 Sequencing kit (Pharmacia Canada Ltd.). RNA analyses .
- RNA from E. coli strains was isolated as described previously (Lloubes et al . (1986) Nuclei c Acid Res . 14:2621-2636) with an additional RNase-free DNase I digestion.
- a gene library was constructed in pTZ18R with chromosomal DNA from S . uberis (su-1) . About 5000 transformants were initially screened for expression of bLf binding protein (Lbp) by colony blotting with 125 I-bLf . One colony with the strongest signal and six with weaker signals were selected and used to make whole cell lysates, which were further tested for their ability to bind 125 I-bLF under non- reducing conditions. The clone with the strongest signal, E. coli pLBP5, generated three major bands; two of them had molecular weights of 165 and 76 kDa which are quite close in size to those of S . uberi s .
- E. coli pLBP5 The presence of free and functionally active recombinant Lbp in the cell lysate and supernatant of E. coli pLBP5 was also detected by performing competitive inhibition assays.
- the E. coli pLBP5 cell lysate and supernatant mixture effectively inhibited 125 I-bLf binding to S . uberis cells in a dose-dependent manner, while samples from E. coli pTZl ⁇ R did not ( Figure 11) .
- the dimer could have been disassociated by urea to monomers which could be further denatured and unfolded, resulting in the apparent molecular weight increase from 76 kDa to 105 kDa.
- a significant increase in the apparent molecular weight of Tbp2 following urea-treatment has been observed in Neisseria meningi tidis by other researchers (Vonder haar et al . (1994) J. Bacteriol . 176:6207-6213).
- the above data also indicates that disulfide bonds are not essential for the formation of the oligomer.
- the lbp sequence contained two potential translation start codons (ATG) at positions 232 and 262 of the DNA sequence. Both are associated with putative Shine-Dalgarno sequences ( Figures 2A-2C) . These start points would give proteins with predicted sizes of 62.857 and 61.454, respectively. The predicted sizes are comparable to 76 KDa molecular weight protein. The reason for the discrepancy between the observed and calculated molecular weights of this protein is not clear. Posttranslational modification, such as lipid modification might have occurred and increased the apparent molecular mass in the SDS-PAGE determination. A similar difference observed in Gram-negative bacteria has been demonstrated to be caused by protein lipid modification (Theisen et al . (1992) Infect . Immun . £0: 826-831; Theisen et al . (1993) Infect . Immun . 61:1793-1798) . The DNA sequence shows two putative -10 and
- the plasmid pLBP5 contained an incomplete gene, mga' , in addition to lbp .
- the pLBP5 molecule was inverted to pLBP5i ( Figure 4) for convenience of description.
- a 991 bp StyI fragment from mga ' was radioactively ( 32 P) labelled as a probe (VP1 in Figure 4) and used to screen an S. uberis gene library.
- a positive E. coli DH5 ⁇ clone was obtained and the restriction enzyme map of the plasmid pMGA14 is shown in Figure 4.
- each of the Bam ⁇ l , Hindi , Hindi11 and Kpnl restriction fragments of pMGA14 ( Figure 4) was individually cloned into the corresponding site of pTZ18R and sequenced from both orientations using universal and reverse primers.
- Plasmid pMGA14 contained the complete ORF of Mga. However, the associated promoter region was not present. Since the 1.5 kb Sphl -Nhel fragment of pLBP5i contained the majority of the 5' region of the mga ' and the complete promoter region, it was inserted into the Sphl and N el sites of pMGA14 to generate pMGA14F which then contained the complete mga gene including the promoter ( Figure 4) . The sequence of a 3558 bp DNA fragment of pMGA14F is presented in Figures 5A-5D.
- Mga the deduced gene product
- Mga is comprised of 499 amino acid residues with a calculated molecular weight of 58,454 Da.
- the N- terminus of Mga lacks the features of signal peptides as described (Simonen and Palva (1993) Microbiol . Rev. 57:109-137), suggesting that it is a cytoplasmic protein.
- Preceding the start codon of mga is a putative ribosome binding site AGGAGA. Sequences resembling the -35 and -10 promoter motifs have also been identified.
- RNA was prepared from S. uberis (su-1) , E. coli DH5 ⁇ (pLBP5) , E. coli DH5 ⁇ (pLBP5L) , E. coli DH5 ⁇ (pMGA14F) and E. coli DH5 ⁇ (pTZ18R) , and used for two Northern blots.
- One blot was probed with the 1.5 kb Hindlll-Hpal internal fragment of lbp (LP1 in Figure 6) .
- a 2.0 kb band was seen in lanes containing RNA from S. uberis, E. coli DH5 ⁇ (pLBP5) and E.
- DNA was prepared and digested with the restriction endonuclease Hindlll and separated on agarose gels.
- uberis strains while the region encoding the N-terminal portion varies greatly.
- the diversity in sizes of chromosomal restriction fragments from the different strains that hybridized with the lbp probes indicates some degree of restriction site heterogeneity (a different location for Hindlll site) among these strains.
- the Lbp gene of S. uberis was cloned in E . coli after screening a gene library by colony blotting with 125 I-bLf.
- E . coli transformants produced functionally active bLf-binding proteins with molecular weights of 76 kDa and 165 kDa, similar to the native proteins produced by S. uberi s .
- bLf with S. uberis Example 1
- Lbp The complex nature of the S. uberis Lbp was further confirmed from the nucleotide sequence analysis. As expected, the two Lbps were encoded by a single ORF of 1,683 bp . It is quite possible that two copies of the translated product interact with each other to form a homodimer. Interactions between subunits could be extensive and extend throughout the length of the molecule due to the existence of the high ⁇ -helical content. Like M proteins (Fischetti, V.A. (1989) Clin . Microbiol . Rev. 2:285-314), Lbp shares significant sequence homology with a number of ⁇ -helical coiled structure-containing mammalian fibrillar proteins such as human myosin heavy chain and kinesin heavy chain.
- the deduced amino acid sequence of Lbp indicated the existence of a signal peptide of 50 amino acids (if translation started at the first ATG start codon) at the N-terminus, as expected for a protein that appears on the outside of a bacterial cell.
- the structure of this signal peptide is comparable to the consensus structures for signal peptides in proteins from Gram positive bacteria described previously (Simonen and Palva (1993) Microbiol . Rev. 57:109-137; Goward et al . (1993)
- VirR49 of an OF + GAS showed less homology (76%) to Mry or VirR of OF " GAS (Podbielski et al . (1995) Infect . Immun . 63.: 9-20) .
- the cytoplasmic location of Mga was suggested by the absence of a signal peptide at the N- terminus of the deduced protein. A potential -10 and -35 promoter was found.
- mry is autoregulated and environmentally regulated in response to the level of C0 2 (Okada et al . (1993) Mol . Mi crobiol . 7:893-903) .
- Expression of mry was stimulated by increased concentrations of C0 2 .
- S. uberi s cells were cultured under conditions without an additional supplementation of C0 2 .
- the absence of a stimulating environment could have resulted in a very low level of mga expression. This could be the reason that Northern blot analysis did not detect any mga transcript from S. uberi s . It would be expected that in recombinant E . coli , mga would not likely be regulated by environmental signals due to the absence of other regulatory components such as the sensing protein.
- the N-terminal region is distal to the streptococcal cell surface, and thus would be expected to be the region of the molecule most exposed to immunological selective pressure. Therefore it is not surprising that the N-terminal region varies in sequence among different serological types of M protein. In contrast, the sequence of the C-terminal region of the molecule should be evolutionarily conserved to assure attachment to the streptococcal surface. Since Lbp has a structure similar to that of M protein, it is not surprising to find that its C- terminal sequence is conserved among strains, whereas the N-terminal region shows variation.
- Tbp2 transferrin binding proteins
- pleuropneumoniae serotypes contain a variable N-terminal half and a conserved C-terminal half (Bunka et al . (1995) Cloning and sequencing of the transferrin-binding protein genes of
- Bacterial strains Bacterial strains, vectors and media.
- S. uberis strain su-1 (ATCC 9927) was obtained from a clinical case of bovine mastitis.
- E. coli strain DH5 ⁇ was used in all transformation experiments.
- E . coli cells were cultured in Luria medium, and the medium for the growth of transformants was supplemented with 50 ⁇ g/ml of ampicillin.
- the plasmid pGH433 (Anderson et al . (1991) Infect . Immun . 59:4110-4116) was used to express the recombinant proteins under the control of an IPTG (isopropyl 3-D-thiogalacto-pyranoside) - inducible promoter.
- Lbp inclusion bodies were dissolved in sample buffer in the presence of 4 M urea and run on an SDS-PAGE gel containing 4 M urea.
- Western blotting was done using convalescent serum from an su-1- infected cow using a 1:75 dilution of cow convalescent serum and a 1:5000 dilution of goat anti-bovine IgG coupled to alkaline phosphatase. Protein purification.
- a culture of E. coli transformants (1 L) was grown to an absorbance at 660 nm of 0.5 and induced with 2 mM IPTG. After 2 h of continuous, vigorous shaking at 37°C, the cells were harvested and the protein inclusion bodies were prepared as described by Gerlach et al . (1992) Infect . Immun . 60:892-898.
- a mid-log phase broth culture (1 L) grown at 30°C was cultured at 42 °C for 2 h with vigorous shaking for protein induction. Cells were harvested by centrifugation, resuspended in 5 ml of 25% sucrose-50 mM Tris-HCl buffer (pH 8.0), and frozen at -70°C.
- Lysis was achieved by the addition of 1 mg of lysozyme in 250 mM Tris-HCl buffer (pH 8.0), 10 min of incubation on ice, addition of 25 ml of a detergent mix (5 parts of 20 mM Tris-HCl buffer, pH 7.4, 300 mM NaCl, 2% deoxycholic acid, 2% Nonidet P-40 and 4 parts of 100 mM Tris-HCl buffer, pH 8.0 , 50 mM EDTA, 2%
- Inclusion bodies were harvested by centrifugation for 30 min at 15,000 x g and resuspended in H 2 0 to a concentration of 5 to 10 mg/ml .
- Antigens for ELISA were purified from SDS-PAGE gels or 4 M urea SDS-PAGE gels by elution.
- Protein purity was estimated by SDS-PAGE and subsequent Coomassie blue staining.
- the protein concentration was determined using Bio-Rad DC protein assay as described by the supplier. Bovine serum albumin (Pierce Chemical Co., Rockford, IL) was used as a standard.
- the amount of target protein vs. total protein was determined after scanning the Coomassie blue stained SDS-PAGE with a Bio-Rad 620 Densitometer .
- the vaccines consisted of proteins emulsified in the adjuvant VSA3 which had been diluted with 0.1 M PBS, pH 7.2. Each 2 ml dose of vaccine contained VSA (0.67 ml), PBS (1.33 ml), and 50 ⁇ g of protein antigen dissolved in 5-10 ⁇ l of 4 M guanidine hydrochloride . Fifteen healthy lactating dairy cows from the Pennsylvania State University Mastitis Research Herd were vaccinated intramuscularly at drying off and again 28 days later. Groups of five cows were given Lbp or adjuvant only.
- the bacterial challenge culture was prepared by rolling the stock bead cultures onto esculin blood agar plates containing 5% whole blood. After 24 hours incubation at 37°C, a single colony was used to inoculate 100 ml of Ultra High Temperature pasteurized (UHT) milk and incubated for 12 hours at 37°C. The 24 hour culture was mixed well and a 100 ⁇ l aliquot was removed to inoculate a second 100 ml of UHT milk. After a second 9 hour incubation at 37°C, the culture was serially diluted in 10 -fold increments using sterile saline.
- UHT Ultra High Temperature pasteurized
- CFU colony forming units
- Total Ig titers for the Lbp antigen were determined by an indirect ELISA.
- Nunc Immunlon-2 plates were coated with antigen in carbonate buffer. Prior to use, the plates were blocked with TBST (100 mM Tris-Cl, pH 8.0; 150 mM NaCl ; 0.05% Tween-20) and 3% BSA for 1 hour. After blocking, the plates were washed with distilled water. Serum and milk samples were serially diluted in 3 -fold increments using TBST containing 1% BSA. Rabbit antisera for the Lbp antigen was also diluted and served as a positive control. Negative control samples contained TBST with 1% BSA.
- the diluted samples and controls were transferred to the coated plates and were incubated for 1 hour at room temperature.
- the plates were washed thoroughly with distilled water and all wells were incubated with a horse radish peroxidase conjugate of goat anti-IgG diluted 1:2000 in TBST containing 1% BSA. Following a 1 hour incubation at room temperature, the plates were washed with distilled water.
- the amount of antibody present in samples was visualized using ABTS substrate.
- the titers of each sample were based on the absorbance reading at 405 nm with a reference wavelength of 495 nm.
- a positive reading for samples was one in which the absorbance was two times the absorbance of the blank (negative control) . Titers were determined by taking the reciprocal of the last dilution giving a positive reading. Consistency among assay plates was monitored by the absorbance reading of positive controls.
- Plasmid pGH-LBP was constructed by inserting the 1.8 kb Sphl -Rsal fragment from pLBP5 into the BamKI site of pGH433 (Fig. 10) which provides a 12 amino acid leader peptide and an IPTG-inducible tac promoter. Before ligation, the insert was treated with mung bean nuclease to remove the 3' overhang from the end generated by Sptil , and the BamHI-cut vector was filled in by the Klenow fragment to produce blunt ends.
- the pGH-LBP contained the carboxy-terminal 96% of the Lbp gene ( lbp) , which was preceded by a 12 amino acid leader peptide and the tac promoter provided by vector pGH433. Analysis of the nucleotide sequence at the fusion site revealed identity to the sequence of the lbp presented in Figure 1.
- Lbp of S. uberis was expressed in E. coli DH5 ⁇ using pGH-LBP. In this system, expression of the recombinant protein was repressed under normal growth conditions. Upon IPTG-induction, the recombinant protein was produced in an aggregated form. The 82 and 90 kD Lbp made up 36% of the total protein. Isolated protein aggregates were dissolved in 4 M guanidine hydrochloride and used for vaccine formulation. Lbp was purified from a 4 M urea SDS- PAGE gel and used as the antigen for ELISA. Both aggregated and purified Lbp were demonstrated to be antigenically active by Western blotting using convalescent serum from S. uberis infected cow. Somatic cell counts in milk following experimental bacterial challenge.
- the mean somatic cell count in milk from challenged quarters of nonvaccinated control animals increased up to 3,000,000 cell/ml 3 days following challenge.
- the challenged quarters of animals vaccinated with Lbp showed a rapid increase in the mean SCC which was close to that in the control group.
- S. uberis Lbp The surface exposure of S. uberis Lbp makes it a potential vaccine candidate by increasing the levels of opsonic antibody in milk and potentiating the speed of PMN recruitment into the mammary gland. Furthermore, the above example shows that Lbp is recognized by bovine serum from an animal which recovered from an S. uberis infection, indicating that the protein is expressed in vivo and cows respond to it immunologically . Based on these considerations, the protective capacity of recombinant Lbp was tested in lactating dairy cows against challenge by S. uberi s .
- Lbp was produced as inclusion bodies in the expression system used, facilitating the purification of large quantities of pure recombinant proteins.
- Lbp did not induce high levels of specific antibodies in the immunized cows, likely due to the formulation parameters.
- bacterial challenge resulted in high somatic cell counts, indicative of mastitis. Therefore, vaccination with Lbp did not prevent the occurrence of mastitis.
- the serological response to vaccination was very poor and therefore it is not possible to draw any conclusions regarding the protective capacity of Lbp from this study.
- Lbp elicited an antibody response in immunized cows. Protection studies are on-going and preliminary results indicate that Lbp is effective in protecting subjects from mastitis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97913041A EP0948528A2 (en) | 1996-11-14 | 1997-11-14 | $i(STREPTOCOCCUS UBERIS) LACTOFERRIN-BINDING PROTEIN |
IL12956697A IL129566A0 (en) | 1996-11-14 | 1997-11-14 | Streptococcus uberis lactoferrin-binding protein |
JP52199298A JP2001504335A (en) | 1996-11-14 | 1997-11-14 | Lactoferrin-binding protein of Streptococcus uberis |
AU50441/98A AU5044198A (en) | 1996-11-14 | 1997-11-14 | (streptococcus uberis) lactoferrin-binding protein |
BR9713355-8A BR9713355A (en) | 1996-11-14 | 1997-11-14 | Lactoferrin-binding protein from streptococcus uberis |
CA002270404A CA2270404A1 (en) | 1996-11-14 | 1997-11-14 | Streptococcus uberis lactoferrin-binding protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3111796P | 1996-11-14 | 1996-11-14 | |
US60/031,117 | 1996-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998021231A2 true WO1998021231A2 (en) | 1998-05-22 |
WO1998021231A3 WO1998021231A3 (en) | 1998-08-27 |
Family
ID=21857732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1997/000867 WO1998021231A2 (en) | 1996-11-14 | 1997-11-14 | Streptococcus uberis lactoferrin-binding protein |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0948528A2 (en) |
JP (1) | JP2001504335A (en) |
KR (1) | KR20000068980A (en) |
AU (1) | AU5044198A (en) |
BR (1) | BR9713355A (en) |
CA (1) | CA2270404A1 (en) |
IL (1) | IL129566A0 (en) |
WO (1) | WO1998021231A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517955B2 (en) | 2002-11-26 | 2009-04-14 | University Of Tennessee Research Foundation | Streptococcus uberis adhesion molecule |
WO2009052572A1 (en) * | 2007-10-25 | 2009-04-30 | The University Of Queensland | Streptococcus m protein, immunogenic fragments, nucleic acids and methods of use |
US20120100174A1 (en) * | 2008-10-06 | 2012-04-26 | The University Of Nottingham | Composition comprising sortase anchored surface proteins of streptococcus uberis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL442091A1 (en) | 2022-08-25 | 2024-02-26 | Uniwersytet Jagielloński | Method and diagnostic composition for detecting mastitis caused by E. coli, S. uberis, S. agalactiae or S. aureus |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014209A1 (en) * | 1992-01-17 | 1993-07-22 | Smithkline Beecham Corporation | Vaccines based on streptokinase |
WO1996041879A1 (en) * | 1995-06-08 | 1996-12-27 | University Of Saskatchewan | Camp factor of streptococcus uberis |
-
1997
- 1997-11-14 KR KR1019997004287A patent/KR20000068980A/en not_active Application Discontinuation
- 1997-11-14 JP JP52199298A patent/JP2001504335A/en active Pending
- 1997-11-14 CA CA002270404A patent/CA2270404A1/en not_active Abandoned
- 1997-11-14 IL IL12956697A patent/IL129566A0/en unknown
- 1997-11-14 AU AU50441/98A patent/AU5044198A/en not_active Abandoned
- 1997-11-14 BR BR9713355-8A patent/BR9713355A/en not_active Application Discontinuation
- 1997-11-14 WO PCT/CA1997/000867 patent/WO1998021231A2/en not_active Application Discontinuation
- 1997-11-14 EP EP97913041A patent/EP0948528A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014209A1 (en) * | 1992-01-17 | 1993-07-22 | Smithkline Beecham Corporation | Vaccines based on streptokinase |
WO1996041879A1 (en) * | 1995-06-08 | 1996-12-27 | University Of Saskatchewan | Camp factor of streptococcus uberis |
Non-Patent Citations (1)
Title |
---|
JIANG M ET AL: "A bovine lactoferrin - binding protein of Streptococcus uberis: Identification of the protein and characterization of the gene." 97TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, MIAMI BEACH, FLORIDA, USA, MAY 4-8, 1997. ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY 97 (0). 1997. 115. ISSN: 1060-2011, XP002066547 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517955B2 (en) | 2002-11-26 | 2009-04-14 | University Of Tennessee Research Foundation | Streptococcus uberis adhesion molecule |
US7812147B2 (en) | 2002-11-26 | 2010-10-12 | University Of Tennessee Research Foundation | Streptococcus uberis adhesion molecule |
US8629249B2 (en) | 2002-11-26 | 2014-01-14 | University Of Tennessee Research Foundation | Streptococcus uberis adhesion molecule |
WO2009052572A1 (en) * | 2007-10-25 | 2009-04-30 | The University Of Queensland | Streptococcus m protein, immunogenic fragments, nucleic acids and methods of use |
US20120100174A1 (en) * | 2008-10-06 | 2012-04-26 | The University Of Nottingham | Composition comprising sortase anchored surface proteins of streptococcus uberis |
US8475809B2 (en) * | 2008-10-06 | 2013-07-02 | The University Of Nottingham | Composition comprising sortase anchored surface proteins of Streptococcus uberis |
Also Published As
Publication number | Publication date |
---|---|
CA2270404A1 (en) | 1998-05-22 |
BR9713355A (en) | 2000-01-25 |
KR20000068980A (en) | 2000-11-25 |
JP2001504335A (en) | 2001-04-03 |
WO1998021231A3 (en) | 1998-08-27 |
IL129566A0 (en) | 2000-02-29 |
EP0948528A2 (en) | 1999-10-13 |
AU5044198A (en) | 1998-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001098334A2 (en) | Streptococcus antigens | |
AU2001270381A1 (en) | Streptococcus antigens | |
US6936259B2 (en) | CAMP factor of Streptococcus uberis | |
PT1320542E (en) | Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof | |
US7749516B2 (en) | Immunization of dairy cattle with GapC protein against Streptococcus infection | |
EP1294771B1 (en) | Chimeric GapC protein from Streptococcus and its use in vaccination and diagnosis | |
WO1998021231A2 (en) | Streptococcus uberis lactoferrin-binding protein | |
JP2001514894A (en) | Neisseria lactoferrin binding protein | |
EP1332155B1 (en) | Immunization of dairy cattle with gapc protein against streptococcus infection | |
EP0635055B1 (en) | Haemophilus somnus immunogenic proteins | |
US6887686B2 (en) | Cloning and expression of Haemophilus somnus transferrin-binding proteins | |
US20030082781A1 (en) | Immunization of dairy cattle with GapC protein against Streptococcus infection | |
US20030165527A1 (en) | Novel fibronectin-binding protein | |
AU2007207883A1 (en) | Streptococcus antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 50441/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2270404 Country of ref document: CA Kind code of ref document: A Ref document number: 2270404 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 335576 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997913041 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1998 521992 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997004287 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997913041 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997004287 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997913041 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997004287 Country of ref document: KR |